ResolveNext AI Brief
The AI and tech developments that every biotech and pharma leader needs to know
Subscribe now to ResolveNext's newsletter covering the AI, data, and tech developments in biotech and pharma. Every other Friday, we will send you the latest data-driven insights emerging from the AI Leadership Dashboard, alerts on new roles and leadership changes, regulatory updates, profiles of new use cases, and our unique take on breaking AI news for pharma and biotech leaders.
New: the AI in Pharma and Biotech Leadership Dashboard, Q4 2026
ResolveNext has launched the AI in Pharma and Biotech Leadership Dashboard for Q4 2026. This unique assessment shows progress on AI in terms of deployment, research, talent, and visibility at the global top 30 pharma companies by revenue, and the top 10% of US companies at each development stage.
Explore the AI leadership dashboard
ResolveNext AI Newsletter
- ResolveNext data from 2,922 AI-related job postings show agentic AI design is the fourth most requested AI skill, behind automation, machine learning, and general AI.
- The MHRA published a 2030 strategy that will apply AI to safety monitoring, and establish a new AI center and a trial-protocol checker.
- The EMA is weighing the use of generative AI in drug manufacturing under a documented control strategy, but offers no method yet for measuring hallucinations.
- Boehringer Ingelheim and Microsoft will test whether digital twins of patients can provide synthetic or hybrid trial control arms, starting in lung health.
